WO2009076388A3 - Targeting vector-phospholipid conjugates - Google Patents

Targeting vector-phospholipid conjugates Download PDF

Info

Publication number
WO2009076388A3
WO2009076388A3 PCT/US2008/086136 US2008086136W WO2009076388A3 WO 2009076388 A3 WO2009076388 A3 WO 2009076388A3 US 2008086136 W US2008086136 W US 2008086136W WO 2009076388 A3 WO2009076388 A3 WO 2009076388A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
peptide
conjugates
processes
phospholipid conjugates
Prior art date
Application number
PCT/US2008/086136
Other languages
French (fr)
Other versions
WO2009076388A2 (en
Inventor
Philippe Bussat
Samir Cherkaoui
Hong Fan (Helen)
Bernard Lamy
Palaniappa Nanjappan
Radhakrishna K. Pillai
Sibylle Pochon
Bo Song
Rolf E. Swenson
Original Assignee
Bracco International B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco International B.V. filed Critical Bracco International B.V.
Publication of WO2009076388A2 publication Critical patent/WO2009076388A2/en
Publication of WO2009076388A3 publication Critical patent/WO2009076388A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.
PCT/US2008/086136 2007-12-11 2008-12-10 Targeting vector-phospholipid conjugates WO2009076388A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/954,130 US7985402B2 (en) 2002-03-01 2007-12-11 Targeting vector-phospholipid conjugates
US11/954,130 2007-12-11

Publications (2)

Publication Number Publication Date
WO2009076388A2 WO2009076388A2 (en) 2009-06-18
WO2009076388A3 true WO2009076388A3 (en) 2009-12-30

Family

ID=39543102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086136 WO2009076388A2 (en) 2007-12-11 2008-12-10 Targeting vector-phospholipid conjugates

Country Status (2)

Country Link
US (3) US7985402B2 (en)
WO (1) WO2009076388A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) * 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US20190046667A1 (en) * 2016-02-01 2019-02-14 Trust Biosonics Inc. Lipid microbubbles and process of making thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078015B2 (en) * 1989-12-22 2006-07-18 Imarx Therapeutics, Inc. Ultrasound imaging and treatment
WO2007067979A2 (en) * 2005-12-09 2007-06-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20070243139A1 (en) * 2002-03-01 2007-10-18 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5773024A (en) 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
CA2083401C (en) 1991-02-22 2003-03-25 Bruce I. Terman Identification of a novel human receptor tyrosine kinase gene
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US20020032313A1 (en) 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0627940B1 (en) 1992-03-05 2003-05-07 Board of Regents, The University of Texas System Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
CA2145985C (en) 1992-10-28 2003-09-16 Napoleone Ferrara Vascular endothelial cell growth factor antagonists
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
ES2249762T3 (en) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. GROWTH FACTOR OF THE VASCULAR ENDOTELIUM 2.
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6130071A (en) 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
CA2270120A1 (en) 1996-10-28 1998-05-07 Pal Rongved Improvements in or relating to diagnostic/therapeutic agents
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020010137A1 (en) 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
WO1998058053A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
ATE320489T1 (en) 1998-03-23 2006-04-15 Genentech Inc GFR-ALPHA3 AND ITS USES
AU5541799A (en) 1998-03-31 1999-11-29 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6548048B1 (en) 1998-04-28 2003-04-15 Amersham Health As Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
DE19941092A1 (en) 1999-08-30 2001-03-01 Philips Corp Intellectual Pty Network with an identifier reduction
EP1248642A4 (en) 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
CA2399022A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
ATE284701T1 (en) 2000-03-02 2005-01-15 Ludwig Inst Cancer Res METHOD FOR TREATING TUMORS WHICH EXPRESS THE VASCULAR ENDOTHELIAL GROWTH FACTOR D
US20010031485A1 (en) 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
WO2001074845A2 (en) 2000-03-31 2001-10-11 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
AU2001264565B2 (en) 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
EP1166798A1 (en) 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
HUP0302779A3 (en) 2000-06-23 2005-12-28 Schering Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
EP1166799A1 (en) 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc Methods of modulating fibrosis
US6895563B2 (en) * 2000-08-15 2005-05-17 Paul K. Dixon Universal laboratory prototyping interface system
US20020091082A1 (en) 2000-09-13 2002-07-11 Aiello Lloyd P. Methods of modulating symptoms of hypertension
US20030082103A1 (en) 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
AU2002245629A1 (en) 2001-03-08 2002-09-24 Targesome, Inc. Stabilized therapeutic and imaging agents
US20030176674A1 (en) 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
WO2003035839A2 (en) 2001-10-24 2003-05-01 Dgi Biotechnologies, Inc. Target specific screening andits use for identifying target binders
US20030125493A1 (en) 2001-10-26 2003-07-03 Harris Stephen H. (Meth)acrylates of oxyalkylated phenolic resins and their use as adhesion promoters
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
EP1501357A4 (en) 2002-05-06 2009-10-21 Genentech Inc Use of vegf for treating bone defects
CA2490009A1 (en) 2002-06-21 2003-12-31 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
NO20026286D0 (en) 2002-12-30 2002-12-30 Amersham Health As New peptides
NO20026285D0 (en) 2002-12-30 2002-12-30 Amersham Health As New peptides
US7183256B2 (en) 2003-03-21 2007-02-27 Cleveland Clinic Foundation TIMP3 as VEGF inhibitor
EP1633304A2 (en) 2003-06-05 2006-03-15 Research Development Foundation Vascular endothelial growth factor fusion constructs and uses thereof
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
US20050043235A1 (en) 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US20050032697A1 (en) 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
JP2005110508A (en) 2003-10-02 2005-04-28 Nec Soft Ltd Growth factor-like protein derived from snake venom having specific binding property to vascular endothelial growth factor receptor 2
US8708909B2 (en) 2004-01-20 2014-04-29 Fujifilm Visualsonics, Inc. High frequency ultrasound imaging using contrast agents
WO2005072417A2 (en) 2004-01-27 2005-08-11 The Ohio State University Research Foundation Vascular endothelial growth factors and methods of their use
JP4175298B2 (en) 2004-07-07 2008-11-05 セイコーエプソン株式会社 Color filter, method for manufacturing the same, electro-optical device, and electronic apparatus
WO2006015385A2 (en) 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078015B2 (en) * 1989-12-22 2006-07-18 Imarx Therapeutics, Inc. Ultrasound imaging and treatment
US20070243139A1 (en) * 2002-03-01 2007-10-18 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2007067979A2 (en) * 2005-12-09 2007-06-14 Bracco International B.V. Targeting vector-phospholipid conjugates

Also Published As

Publication number Publication date
US20080152594A1 (en) 2008-06-26
WO2009076388A2 (en) 2009-06-18
US20130266519A1 (en) 2013-10-10
US7985402B2 (en) 2011-07-26
US20110286936A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
WO2010059253A3 (en) Methods and compositions for localized agent delivery
WO2009076388A3 (en) Targeting vector-phospholipid conjugates
WO2008137758A3 (en) Amino acid lipids and uses thereof
HK1130186A1 (en) Phospholipid analogue for the in vivo diagnosis of cancers
WO2010046900A3 (en) Rgd-containing peptidomimetics and uses thereof
EP4241767A3 (en) Novel lipids and compositions for the delivery of therapeutics
WO2011053901A3 (en) Magnetic nanostructures as theranostic agents
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2012054500A3 (en) Compositions for drug administration
WO2009114776A3 (en) Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
MX335965B (en) Antibodies specific for the protofibril form of beta-amyloid protein.
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
EP3520816A3 (en) Anti-gcc antibody molecules and related compositions and methods
WO2007092772A8 (en) Protein formulations
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
BR112012006283A2 (en) stabilized adamts13 formulation, method for manufacturing a stabilized adamts13 formulation, kit, and methods for treating or preventing a disease and for treating or preventing a stroke
WO2007035612A3 (en) Polyphenol conjugates as rgd-binding compounds and methods of use
GB0718957D0 (en) Optical imaging agents
EP4124346A3 (en) Compositions and methods for treating diseases
CY1115725T1 (en) UNIONS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF BETA-AMYLOIDIC DISEASES AND CONCLUSIONS
WO2007035474A3 (en) Transdermal delivery peptides and method of use thereof
WO2008064910A3 (en) Metastasis-specific peptides and their diagnostic and therapeutic applications
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2012139080A3 (en) Lipid-based nanoparticles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859380

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859380

Country of ref document: EP

Kind code of ref document: A2